Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.43 |
| ▸ | PDCD1LG2 | Q9BQ51 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CASR | P41180 | 1/20 | 0.36 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703961 | 0.75 | PDCD1LG2 (0.41) | CD274PDCD1LG2 | |
| SCHEMBL3741159 | 0.74 | PDCD1LG2 (0.38) | CD274PDCD1LG2MEN1KMT2A | |
| SCHEMBL3710213 | 0.72 | PDCD1LG2 (0.37) | CD274PDCD1LG2 | |
| SCHEMBL3747332 | 0.71 | KDM4E (0.53) | CD274PDCD1LG2KMT2AADRB2 | |
| SCHEMBL3706175 | 0.71 | KDM4E (0.53) | CD274PDCD1LG2KMT2AADRB2 | |
| SCHEMBL3718739 | 0.71 | KDM4E (0.53) | CD274PDCD1LG2KMT2AADRB2 | |
| SCHEMBL3717472 | 0.70 | PDCD1LG2 (0.36) | CD274PDCD1LG2MEN1KMT2A | |
| SCHEMBL25868650 | 0.70 | HPGD (0.52) | MEN1HPGDKMT2AADRB2ADRB1 | |
| SCHEMBL3717469 | 0.69 | LMNA (0.40) | MEN1HPGDTSHRKMT2ANR2E1 | |
| SCHEMBL3743643 | 0.69 | PDCD1LG2 (0.41) | CD274PDCD1LG2MEN1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | CD274 4459/4885PDCD1LG2 3904/4885MEN1 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.